R
RDS
MultiSense wearable patch and cloud for continuous remote patient monitoring
About RDS
RDS (Rhythm Diagnostic Systems) is a Strasbourg MedTech company founded in 2020 that develops, manufactures and markets MultiSense, a CE-marked (MDR) wearable remote-patient-monitoring solution combining a multi-parameter patch with a cloud platform and clinical support services. The patch continuously tracks key vitals such as heart rate, respiratory rate and oxygen saturation to support short-stay and post-operative pathways, earlier discharge and safer home monitoring; devices are designed for cleaning, refurbishment and reuse. MultiSense is deployed in hospitals across France, Belgium and Germany and listed with French public purchasing networks RESAH and UniHA. In September 2025 RDS raised a €14 million Series A equity round led by Bpifrance’s SPI fund with Critical Path Ventures, MACSF and Capital Grand Est, bringing total capital raised to about €28 million when including earlier equity and French non-dilutive/France 2030 support kept distinct from this Series A. Proceeds fund European commercialisation, industrialisation in France, reimbursement trials and preparation for FDA/US launch around 2028. Sources: EU-Startups 29 Sep 2025.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Strasbourg, France
- Employees
- 152
- Open positions
- 1
- Dealroom signal
- 88.4/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Remote Monitoring, Core AI
- Technology
- Artificial Intelligence, Hardware, Big Data, Deep Tech, Connected Device
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2025 | $15M | $62M | Capital Grand Est · MACSF · Critical Path Ventures · Bpifrance | ↗ |
| SEED✓Equity / VC | Dec 2023 | $2.2M | $8.8M | Capital Grand Est · MACSF | ↗ |
Growth signals
Latest recorded traffic for RDS is 1.2K monthly website visits, down 47.8% over the last three months. RDS's team grew 14.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Capital Grand Est
MACSF
Series A2 investors entered at this stage
Bpifrance
Critical Path Ventures
Other known investors9 additional known investors
Institute of Image-Guided Surgery
Bernard Daugeras
Elie Lobel
IRCAD- MRMichel Ronc
- SESam Eletr
University of Strasbourg
Future4Care
SEMIA
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about RDS on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RDS’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.